Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung Cancer
NCT06779539
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
33
Enrollment
OTHER
Sponsor class
Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG:
Ensartinib
Sponsor
West China Hospital